Search the Newsreel

Twist Bioscience (TWST) director sells 2,240 shares to cover RSU tax

Twist Bioscience director Katryn Blake sold 2,240 shares of common stock on August 12, 2026, at $122.88 per share. This transaction was not a discretionary trade but was executed to cover tax liabilities arising from the vesting of Restricted Stock Units. Following the sale, …

Wheels Up (UP): Whitebox reports 2.8% stake and ends Kore ownership group

Whitebox Advisors LLC and Whitebox General Partner LLC have reported an updated ownership stake in Wheels Up Experience Inc. As of June 30, 2026, Whitebox beneficially owns 1,021,597 shares of Class A Common Stock, representing approximately 2.8% of the outstanding shares. The filing also …

Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap

A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The …

Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The …

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts

Caribou Biosciences (NASDAQ:CRBU) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.75. The company's shares recently traded down 2.2% to $1.57. Caribou Biosciences reported a narrower-than-expected quarterly loss but missed revenue estimates, and institutional investors own …

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

Caribou Biosciences (NASDAQ: CRBU) reported second-quarter EPS of $-0.240, beating analyst estimates by $0.07, and revenue of $2.65 million, surpassing the consensus estimate of $2.3 million. Despite the earnings beat, the company's stock price has declined by -24.770% in the last three months and …

Solésence, Inc. (SLSN) flags inventory costing error and delays Q2 2026 10-Q filing

Solésence, Inc. (SLSN) announced a delay in filing its Q2 2026 Form 10-Q due to the discovery of an improper inventory costing methodology. The company is currently determining the necessary corrective measures and the financial impact of this error. Solésence expects to file the …

RPG Life Sciences accepts Deepak Shukla's resignation as API head

Satellos Bioscience (MSLE) enters $50M at-the-market share deal

RPG Life Sciences completes API business transfer to subsidiary

New Providence Acquisition Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Kingfa Science net profit up 111% in Q1FY27 to ₹802 crore

Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside

Satellos Bioscience Inc.'s average 12-month price target has been adjusted to $21.78, down from $22.04, according to estimates from 6 analysts. This new target suggests a potential upside of approximately 122% from the August 13 closing price. The consensus rating among 7 covering analysts …

Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A

Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …

Van Eck Associates (EU) reports 7.8% beneficial stake in enCore Energy

Van Eck Associates Corporation has filed an amended beneficial ownership statement, revealing a 7.8% beneficial stake in enCore Energy Corp, totaling 15,159,056 ordinary shares. Van Eck Associates holds sole voting and dispositive power over these shares, and the VanEck Uranium and Nuclear ETF has …

Achieve Life Sciences (ACHV) launches $150M at-the-market stock program

Achieve Life Sciences (ACHV) has established a $150 million at-the-market (ATM) equity offering program with Jefferies LLC as the sales agent. The company plans to sell common stock periodically, with net proceeds intended for the commercialization of cytisinicline, funding a Phase 3 clinical trial …

Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise

Jeremy Hayden, an insider at Sight Sciences (SGHT), filed a Form 144 indicating his intent to sell 48,000 shares of common stock on August 14, 2026, following a stock option exercise. The planned sale has an aggregate market value of $395,878.84. This filing also …

Diana Shipping Inc. 撤回了收購 Genco Shipping & Trading 的要約，原因是 Genco 董事會提出了無理要求。

Diana Shipping Inc. 已撤回對 Genco Shipping & Trading 的收購要約，理由是 Genco 董事會提出了不合理的要求。Diana Shipping 認為 Genco 的要求過高且不符合其股東的最佳利益，因此決定終止這項交易。此舉反映了雙方在交易條件上未能達成一致。

Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing

Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …

Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …

Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Senti Biosciences Holdings, Inc. reported its earnings results for the second quarter and six months ended June 30, 2026. For the second quarter, the company's net loss decreased to USD 12.75 million from USD 14.73 million a year prior, with basic and diluted loss …

Why (ASMB) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …

Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants

Baker Bros. Advisors and its related entities have disclosed a 5.2% beneficial ownership stake in IDEAYA Biosciences, Inc. (IDYA), totaling 5,010,030 shares based on 96,375,637 shares outstanding as of June 30, 2026. The firm also holds prefunded warrants with a low exercise price but …

Tencent Stock Slips Again as AI Spending Outruns Profit Growth

This article first appeared on GuruFocus. Tencent Holdings (TCEHY), the Chinese gaming, social-media and cloud powerhouse, slipped 0.2% to HK$440 Friday after dropping 3.7% Thursday. The headline numbers were solid enough: second-quarter revenue jumped 11% to RMB204.8 billion. But IFRS profit attributable to shareholders …

ARK reports 9.59% stake in Pacific Biosciences (PACB)

ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over …

Enterprise value to EBITDA forward of Agency Group Australia Ltd – ASX:AU1

Gilead Sciences (GILD) Could Be 8% Overvalued As AI Deal And Q2 Results Lift Shares

Gilead Sciences (GILD) is gaining investor attention due to a new AI collaboration with Nucleai and positive Q2 results, though some analyses suggest it might be overvalued by about 8%. The company is transitioning into a multi-platform biopharma, but differing valuation models present varied …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

American Century discloses 5.2% Benchmark Electronics (BHE) stake in 13G filing

American Century entities and the Stowers Institute have filed a Schedule 13G, disclosing beneficial ownership of 5.2% of Benchmark Electronics, Inc. (BHE) common stock, totaling 1,870,433 shares as of June 30, 2026. American Century ETF Trust also reported beneficial ownership of 5.0% or 1,793,588 …

Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …

Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung

TMC Life Sciences Berhad Declares First and Final Single-Tier Dividend in Respect of the Financial Year Ended 30 June 2026

Gilead wins appeals court ruling against overseas drug imports

A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …

Aarvi Encon net profit up 43% in Q1FY27; EBITDA margin slips to 2.61%